| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Transarterial chemoembolization outcomes for advanced hepatocellular carcinoma vs sorafenib and best supportive care in a sub-Saharan African cohort
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sanju Sobnach, Karla Christina Sousa Silva, Ebtesam Abdel-Rashid Abdel-Shafy, Muhammad Emmamally, Catherine Wendy Spearman, Marc Bernon, Mark W Sonderup, Keith Venter, Inae Kim, Urda Kotze, Rajshree Segobin, Dale K Creamer, Stefano Cacciatore, Luiz Fernando Zerbini and Eduard Jonas |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| International Centre for Genetic Engineering and Biotechnology |
|
| Harry Crossley Foundation at the University of Cape Town |
|
|
| Corresponding Author |
Luiz Fernando Zerbini, Director, Cancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Anzio Road, Observatory, Cape Town 7925, Western Cape, South Africa. luiz.zerbini@icgeb.org |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Tyrosine kinase inhibitor; Best supportive care; Outcomes |
| Core Tip |
Hepatocellular carcinoma is one of the most prevalent cancers on the African continent. In low-income countries, transarterial chemoembolization (TACE) is frequently offered as a life-prolonging treatment option, even for late-stage hepatocellular carcinoma patients. This single-center retrospective cohort study evaluated the outcomes of TACE in Barcelona Clinic Liver Cancer (BCLC) stage C and D patients. Furthermore, outcomes were compared in three matched cohorts’ patients with BCLC stage C and D treated with TACE, patients who received tyrosine kinase inhibitors, and patients who were treated with best supportive care. Furthermore, the overall survival of patients with BCLC stage C disease undergoing TACE was significantly better compared to tyrosine kinase inhibitors and best supportive care. Finally, portal vein tumor infiltration, high aspartate aminotransferase and gamma-glutamyl transferase levels were significant risk factors for poor outcomes. |
| Publish Date |
2025-12-10 07:48 |
| Citation |
Sobnach S, Sousa Silva KC, Abdel-Shafy EAR, Emmamally M, Spearman CW, Bernon M, Sonderup MW, Venter K, Kim I, Kotze U, Segobin R, Creamer DK, Cacciatore S, Zerbini LF, Jonas E. Transarterial chemoembolization outcomes for advanced hepatocellular carcinoma vs sorafenib and best supportive care in a sub-Saharan African cohort. World J Gastroenterol 2025; 31(46): 112249 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i46/112249.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i46.112249 |
